BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 16988579)

  • 1. Clofarabine and nelarabine: two new purine nucleoside analogs.
    Gandhi V; Plunkett W
    Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
    Larson RA
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clofarabine in pediatric acute leukemia: current findings and issues.
    Hijiya N; Barry E; Arceci RJ
    Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nursing considerations for optimal outpatient management of adult patients with leukemia treated with clofarabine.
    Dressel A; Kwari M; McGreal AM
    Clin J Oncol Nurs; 2011 Feb; 15(1):E13-23. PubMed ID: 21278032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Older and new purine nucleoside analogs for patients with acute leukemias.
    Robak P; Robak T
    Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clofarabine for the treatment of acute lymphoblastic leukemia.
    Jeha S; Kantarjian H
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):113-8. PubMed ID: 17288522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
    Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Kadia TM; Gandhi V
    Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia.
    Steinherz PG; Meyers PA; Steinherz LJ; Jeha S
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):656-8. PubMed ID: 17805046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine.
    Jeha S
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1137-44, viii. PubMed ID: 19825457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofarabine: a new treatment option for patients with acute myeloid leukemia.
    Larson ML; Venugopal P
    Expert Opin Pharmacother; 2009 Jun; 10(8):1353-7. PubMed ID: 19463072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of clofarabine: a nucleoside analogue for treating cancer.
    Bonate PL; Arthaud L; Cantrell WR; Stephenson K; Secrist JA; Weitman S
    Nat Rev Drug Discov; 2006 Oct; 5(10):855-63. PubMed ID: 17016426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
    Gandhi V; Kantarjian H; Faderl S; Bonate P; Du M; Ayres M; Rios MB; Keating MJ; Plunkett W
    Clin Cancer Res; 2003 Dec; 9(17):6335-42. PubMed ID: 14695132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.
    Parker WB; Shaddix SC; Gilbert KS; Shepherd RV; Waud WR
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):253-61. PubMed ID: 19002461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel purine nucleoside analogues for hematological malignancies.
    Korycka A; Lech-MaraƄda E; Robak T
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nelarabine: efficacy in the treatment of clinical malignancies.
    Roecker AM; Allison JC; Kisor DF
    Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
    Cooper T; Kantarjian H; Plunkett W; Gandhi V
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1417-23. PubMed ID: 15571270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
    J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.